PeptidePedia The community reference

Contributions of ReceptorRhoda

User contributions·36 logged edits·page 1 of 1

Contributions by ReceptorRhoda, newest first. This list covers edits recorded in the site's change log; the editor's lifetime total of 11,955 edits includes activity predating the current log.

  1. 09:07, 16 Jul 2026 (diff | hist) Proglucagon 6,709 ±0 expand §Gene and transcript
  2. 10:51, 15 Jun 2026 (diff | hist) Receptor bias 4,477 ±0 clarify that the receptor is expressed outside the pancreas
  3. 13:39, 13 Jun 2026 (diff | hist) Albumin binding half-life extension 6,399 ±0 unpipe a link that did not need piping
  4. 10:03, 31 May 2026 (diff | hist) Sharps disposal 11,037 +1,605 add the diluent volume the example assumes
  5. 10:30, 25 May 2026 (diff | hist) Talk:Receptor bias 537 +185 /* Two senses of bias */ new section
  6. 10:20, 20 Apr 2026 (diff | hist) Talk:Melanotan II 537 +169 /* Non-selectivity as the theme */ new section
  7. 14:05, 16 Apr 2026 (diff | hist) Talk:Amylin receptor agonist 611 +196 /* Calcitonin receptor cross-activity */ reply
  8. 08:40, 12 Apr 2026 (diff | hist) Talk:Tirzepatide 959 +153 /* Is "GIP-biased" the right term? */ reply
  9. 11:50, 11 Apr 2026 (diff | hist) Talk:Tirzepatide 537 +191 /* Is "GIP-biased" the right term? */ new section
  10. 15:07, 6 Apr 2026 (diff | hist) Liquid chromatography-mass spectrometry 4,463 ±0 m add the forced-degradation conditions the claim rests on
  11. 10:30, 2 Apr 2026 (diff | hist) Talk:GLP-1 receptor 400 +254 /* Immunohistochemistry caveat */ new section
  12. 11:20, 27 Mar 2026 (diff | hist) Talk:CagriSema 537 +217 /* Why not a unimolecular design? */ new section
  13. 11:45, 14 Mar 2026 (diff | hist) Talk:Orforglipron 537 +175 /* Species selectivity */ new section
  14. 14:52, 8 Mar 2026 (diff | hist) Talk:Glucagon-like peptide-1 748 +229 /* Readability of the signalling section */ reply
  15. 12:19, 5 Mar 2026 (diff | hist) Talk:Dipeptidyl peptidase-4 611 +180 /* Is GLP-1(9-36) inert or not? */ reply
  16. 09:35, 21 Jan 2026 (diff | hist) Talk:Triple agonist 400 +136 /* Ratio comparisons across publications */ new section
  17. 21:29, 14 Jan 2026 (diff | hist) Orforglipron 5,647 ±0 rm a duplicated category
  18. 04:40, 18 Dec 2025 (diff | hist) Satiety signalling 5,593 ±0 de-orphan
  19. 18:36, 22 Sep 2025 (diff | hist) Bacterial endotoxin test 5,317 +229 state that ultraviolet response is not uniform across impurities
  20. 22:12, 28 Jul 2025 (diff | hist) Triple agonist 3,987 ±0 clarify that the peptide backbone is acylated rather than PEGylated
  21. 13:03, 13 Jul 2025 (diff | hist) Arcuate nucleus 5,017 +654 expand §Neuronal populations
  22. 20:47, 7 Jul 2025 (diff | hist) Glucagon-like peptide-1 12,102 +672 m add the enteroendocrine cell type responsible for secretion
  23. 15:04, 26 Jun 2025 (diff | hist) High-performance liquid chromatography 6,203 ±0 m clarify the difference between related substances and total impurities
  24. 15:09, 28 Apr 2025 (diff | hist) Albumin binding half-life extension 4,872 ±0 m split §Physiology from §Pharmacological exploitation
  25. 03:55, 21 Apr 2025 (diff | hist) Solid-phase peptide synthesis 5,107 +31 m state the difference between a validated shipper and an insulated box
  26. 19:26, 16 Apr 2025 (diff | hist) Glucose-dependent insulinotropic polypeptide 6,711 +25 clarify that the incretin effect is defined by the oral–intravenous comparison
  27. 21:27, 8 Apr 2025 (diff | hist) Insulin syringe unit conversion 4,444 +780 add the note that vial overfill is not assumed
  28. 15:41, 17 Mar 2025 (diff | hist) Cold chain 20,222 +1,422 expand §Packaging and qualification
  29. 10:41, 17 Feb 2025 (diff | hist) GLP-1 receptor agonist 9,254 ±0 m move the trade-name history out of the lead and into §Regulatory history
  30. 02:00, 10 Jan 2025 (diff | hist) Satiety signalling 4,078 +104 give the magnitude of the incretin effect as a percentage of the insulin response
  31. 20:27, 5 Nov 2024 (diff | hist) C-peptide 2,537 ±0 expand §Use in assessment
  32. 06:42, 9 Oct 2024 (diff | hist) Proglucagon 3,075 ±0 rm a duplicated category
  33. 14:08, 26 Sep 2024 (diff | hist) Triple agonist 2,043 +872 m move a stray full stop inside the reference
  34. 14:37, 20 Sep 2024 (diff | hist) Beta cell function 2,291 ±0 m expand §Change under treatment and weight loss
  35. 13:32, 28 Aug 2024 (diff | hist) Glucose-dependent insulinotropic polypeptide 4,346 +829 attribute the gastric-emptying effect to the study that measured it
  36. 16:15, 7 Aug 2024 (diff | hist) Insulin secretion 1,546 ±0 m correct the second-messenger pathway named in the lead